NASDAQ:SIBN - SI-BONE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $40.57
Forecasted Upside: 29.09 %
Number of Analysts: 6
Breakdown:
0 Sell Ratings
0 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$31.43 As of 06/23/2021 01:00 AM ET

▲ +0.04 (0.13%)

1 month | 3 months | 12 months

Get New SI-BONE Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SIBN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SIBN

^$40.57

▲ +29.09% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for SI-BONE in the last 3 months. The average price target is $40.57, with a high forecast of $43.00 and a low forecast of $35.00. The average price target represents a 29.09% upside from the last price of $31.43.

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in SI-BONE.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/31/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/30/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/28/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/26/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/25/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/25/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/8/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Buy	$40.00	Medium
6/8/2021	Citigroup	Initiated Coverage	Buy		Medium
5/4/2021	Truist Securities	Boost Price Target		$35.00 ➝ $43.00	Medium
5/4/2021	Truist	Boost Price Target		$35.00 ➝ $43.00	High
5/4/2021	Canaccord Genuity	Boost Price Target	Buy	$39.00 ➝ $40.00	High
5/4/2021	Needham & Company LLC	Boost Price Target	Buy	$34.00 ➝ $42.00	High
5/4/2021	Morgan Stanley	Boost Price Target	Overweight	$38.00 ➝ $41.00	High
4/19/2021	Morgan Stanley	Boost Price Target	Overweight	$35.00 ➝ $38.00	High
3/9/2021	Morgan Stanley	Boost Price Target	Overweight	$32.00 ➝ $35.00	High
3/9/2021	Needham & Company LLC	Lower Price Target	Buy	$35.00 ➝ $34.00	High
2/1/2021	Needham & Company LLC	Reiterated Rating	Buy	$27.00	Low
1/8/2021	JMP Securities	Boost Price Target	Outperform	$27.00 ➝ $35.00	Medium
12/17/2020	Canaccord Genuity	Boost Price Target	Buy	$30.00 ➝ $34.00	High
12/16/2020	Needham & Company LLC	Boost Price Target	Buy	$28.00 ➝ $35.00	N/A
12/15/2020	Morgan Stanley	Boost Price Target	Overweight	$25.00 ➝ $32.00	Low
9/30/2020	JMP Securities	Boost Price Target	Outperform	$22.00 ➝ $27.00	High
8/4/2020	Morgan Stanley	Boost Price Target	Overweight	$20.00 ➝ $25.00	High
8/4/2020	Canaccord Genuity	Reiterated Rating	Buy	$24.00	High
8/4/2020	Needham & Company LLC	Boost Price Target	Buy	$22.00 ➝ $24.00	High
6/15/2020	Cantor Fitzgerald	Initiated Coverage	Buy	$25.00	Low
6/8/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium
5/29/2020	Needham & Company LLC	Reiterated Rating	Buy	$22.00	High
5/5/2020	JMP Securities	Lower Price Target	Market Outperform	$27.00 ➝ $22.00	Medium
5/5/2020	Morgan Stanley	Boost Price Target	Overweight	$18.00 ➝ $20.00	High
5/5/2020	Needham & Company LLC	Lower Price Target	Buy	$27.00 ➝ $22.00	High
3/27/2020	Morgan Stanley	Lower Price Target	Overweight	$24.00 ➝ $18.00	High
2/19/2020	Needham & Company LLC	Initiated Coverage	Buy	$27.00	High
1/7/2020	SunTrust Banks	Initiated Coverage	Buy	$27.00	Low
12/17/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$27.00	Low
11/12/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$23.00	Low
11/12/2018	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight	$24.00	Low
11/12/2018	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$25.00	Low
11/12/2018	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$27.00	Low

(Data available from 6/23/2016 forward)

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Today's Range

Now: $31.43

$31.21

$31.91

50 Day Range

MA: $32.24

$29.40

$35.96

52 Week Range

Now: $31.43

$14.43

$37.21

Volume

277,819 shs

Average Volume

273,397 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of SI-BONE?

The following sell-side analysts have issued stock ratings on SI-BONE in the last year: Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, JMP Securities, Morgan Stanley, Needham & Company LLC, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for SIBN.

What is the current price target for SI-BONE?

7 Wall Street analysts have set twelve-month price targets for SI-BONE in the last year. Their average twelve-month price target is $40.57, suggesting a possible upside of 29.2%. Truist has the highest price target set, predicting SIBN will reach $43.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $35.00 for SI-BONE in the next year.
View the latest price targets for SIBN.

What is the current consensus analyst rating for SI-BONE?

SI-BONE currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SIBN will outperform the market and that investors should add to their positions of SI-BONE.
View the latest ratings for SIBN.

What other companies compete with SI-BONE?

Other companies that are similar to SI-BONE include Glaukos, Cantel Medical, NuVasive, Merit Medical Systems, AtriCure, Haemonetics, Axonics, iRhythm Technologies, Inovio Pharmaceuticals, Silk Road Medical, Luminex, Cardiovascular Systems, Pulmonx, Alphatec and Treace Medical Concepts.

How do I contact SI-BONE's investor relations team?

SI-BONE's physical mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company's listed phone number is 408-207-0700 and its investor relations email address is [email protected] The official website for SI-BONE is www.si-bone.com.